The complement system in COVID-19

Research output: PhD ThesisPhd-Thesis - Research and graduation internal

Abstract

In this thesis, complement activation in COVID-19 was described and the effect of targeting complement factor C5a with the monoclonal antibody vilobelimab in severely and critically ill COVID-19 patients. The aim was to determine the effect of vilobelimab on mortality and safety in critically ill COVID-19 patients, to assess its effects on biomarkers of inflammation and coagulation in severely
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • University of Amsterdam
Supervisors/Advisors
  • Vlaar, Alexander, Supervisor
  • van de Beek, Diederik, Supervisor
  • Brouwer, Matthijs, Co-supervisor
  • de Bruin, Sanne, Co-supervisor
Award date31 May 2024
Publication statusPublished - 2024

Cite this